Plain-English translation of NCT07171723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Researchers are studying how a substance called LEAP2 affects hunger and eating when given to people already taking semaglutide for weight loss. Semaglutide works by reducing appetite, but scientists want to understand whether blocking another hunger signal in the body (called ghrelin) could make the medication work even better. This is an early-stage study to explore whether these two approaches to controlling hunger might complement each other.
We know semaglutide helps people lose weight by suppressing appetite, but scientists don't fully understand all the hunger signals at play in the body. This study exists to find out whether blocking an additional hunger hormone could enhance weight loss treatment or help people feel fuller longer while on this medication.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic twice for study days spaced a week or two apart. On each visit, you would receive a 6-hour intravenous infusion (a thin tube in your vein)—one day with the test substance and one day with a placebo (salt water). During and after the infusion, researchers would measure your hunger feelings, let you eat as much as you want from a meal, take blood samples to check hormone and glucose levels, and use other tests to track how your body is responding. The study is designed so you won't know which infusion you're getting on which day.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Denmark